FLGT · XBRL financial data

Fulgent Genetics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (FLGT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	422	993	619	289	283	323
Cost of revenue	90	216	252	185	176	192
Gross profit	332	777	367	104	107	131
Research and development	12	24	29	41	49	54
General and administrative	15	51	111	89	88	117
Total operating expenses	42	101	188	300	181	222
Operating income (loss)	290	676	179	(196)	(74)	(91)
Interest income	—	—	6	22	31	31
Interest expense	0	0	0	0	(0)	0
Other income (expense)	—	—	1	0	1	0
Income tax expense (benefit)	73	175	42	1	(8)	(8)
Net income (loss)	214	507	143	(168)	(43)	(61)
Weighted average shares, basic millions of shares	23	29	30	30	30	31
Weighted average shares, diluted millions of shares	24	31	31	30	30	31

Fiscal years (FLGT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	87	165	80	97	55	50
Marketable securities	212	—	—	—	203	286
Marketable securities, non-current	133	485	327	424	570	369
Accounts receivable	184	139	53	51	69	85
Total current assets	524	612	628	508	354	550
Property and equipment, net	40	62	81	83	106	113
Right-of-use asset	1	7	15	11	5	5
Goodwill	—	51	143	22	22	25
Total assets	700	1,279	1,386	1,235	1,220	1,214
Accounts payable	26	20	23	15	18	19
Accrued liabilities	8	18	25	31	24	34
Total current liabilities	130	105	88	73	73	85
Lease liability, non-current	1	5	9	7	4	4
Total liabilities	131	113	116	102	91	107
Retained earnings	151	658	801	633	590	530
Total stockholders' equity	569	1,159	1,267	1,136	1,133	1,112
Total liabilities and equity	700	1,279	1,386	1,235	1,220	1,214
Common shares outstanding (cover page) millions of shares	29	30	30	30	31	31

Fiscal years (FLGT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	214	507	143	(168)	(43)	(61)
Stock-based compensation	8	16	33	43	44	40
Depreciation and amortization	3	11	33	26	25	24
Net cash from operating activities	141	539	254	27	21	(102)
Purchases of property and equipment	35	24	19	22	40	23
Net cash from investing activities	(326)	(547)	(261)	39	(58)	111
Proceeds from issuing common stock	246	89	—	—	—	—
Share repurchases	0	—	74	25	0	11
Net cash from financing activities	261	85	(77)	(48)	(5)	(15)
Net change in cash	75	77	(85)	18	(42)	(5)

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Fulgent Genetics	26	85	(24)*	27.5M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
BillionToOne	562	123	13*	not reported	—	Q3 FY26 10-QSep 30, 2026
Fortrea Holdings	221	692	61*	96.5M	—	Q3 FY26 10-QSep 30, 2026
Celcuity	182	not reported	(55)*	48.9M	13.6 quarters	Q2 FY26 10-QJun 30, 2026
Exagen	25	20	4*	24.2M	—	Q2 FY26 10-QJun 30, 2026
Castle Biosciences	62	104	15*	30.5M	—	Q2 FY26 10-QJun 30, 2026
Personalis	98	26	(27)*	108.4M	6.7 quarters	Q3 FY26 10-QSep 30, 2026
Lumexa Imaging Holdings	70	264	33*	96.1M	—	Q2 FY26 10-QJun 30, 2026
Freenome	0.4	not reported	(0.1)*	not reported	3.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.